Trump Rejects Iran Proposal as War Tensions Push Oil Prices Higher 
Oil Prices Slip Amid UAE’s OPEC Exit and Ongoing Iran Conflict Concerns 
Australia Inflation Surges in March as Fuel Prices Spike Amid Middle East Conflict 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Asian Stocks Mixed as BOJ Holds Rates, Oil Prices and Fed Outlook Weigh on Markets 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Bank of England Set to Hold Interest Rates as Inflation Risks and Iran War Impact Loom 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Oil Prices Rise Amid U.S.-Iran Tensions and Strait of Hormuz Deadlock 
BOJ Rate Decision in Focus as Yen, Inflation, and Nikkei Hang in Balance 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
South Korean drugmaker Daewoong Pharmaceutical Co. inked a US$430 million deal to provide US pharmaceutical venture firm Neurogastrx Inc. with its technology for fexuprazan, the novel drug candidate for gastroesophageal reflux.
The technology deal with Neurogastrx made the US the fourth country that the South Korean firm has signed technology deals with, after China, Brazil, and Mexico.
The said countries account for almost 40 percent of the global gastrointestinal disorder market.
The combined value of the deals is already over 1 trillion won.
Daewoong Pharmaceutical will also receive 13.5 percent of Neurogastrx's shares.
Daewoong Pharmaceutical claims that fexuprazan, a class of potassium-competitive acid blockers, exhibited a cure rate of 99 percent during the phase three clinical trials and is expected to win approval from local drug authorities soon.
Neurogastrx is a privately-held biopharmaceutical company that develops therapies for gastrointestinal disorders.
